GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It

2Firsts Events by 2FIRSTS Charlotte, edited by Sophia Lv
May.30.2024
GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

The "GTNF InFocus 2024" was held online as scheduled on the evening of May 22, Beijing time. The forum focused on two core themes: "Myths about Nicotine and Its Harms" and "The Nicotine Industry from an Agricultural Perspective."

 

The forum began with a welcome address from GTNF founder and Executive Director of the GTNF Trust Fund, Elise Rasmussen. In her speech, Rasmussen highlighted the uncertainty in global nicotine regulation, emphasizing the volatile tobacco policies in the UK and US since the end of last year. She also expressed gratitude to the experts sharing their insights at the forum.

 

Dispelling Nicotine Myths: A "Horror" Narrative Around E-Cigarettes

 

The first keynote speech was delivered by Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School. His presentation focused on the pathological characteristics of nicotine and synthetic nicotine, detailing the molecular structure, receptors, and anatomical absorption process in the human body.

 

Professor Strupp reiterated his key point that nicotine, as a molecular structure, is not carcinogenic. He vividly compared e-cigarettes to traditional combustible cigarettes using the analogy of electric cars versus fuel cars, highlighting that the underlying logic of e-cigarettes is similar to the advantages of electric cars, which are "a cleaner process and less damage."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
Michael Strupp, Professor of Neurology at Ludwig Maximilian University of Munich Medical School

 

Following Professor Strupp's speech, James Murphy, Director of Research and Science at British American Tobacco (BAT), delivered the second keynote speech. Murphy, who previously led BAT's Group of Reduced Risk Products (PRRP) Science and was the product manager for the Americas and Sub-Saharan Africa regions, drew from his experiences in developing markets to argue that the public health community needs to adopt a consistent scientific viewpoint on new-generation tobacco products to provide regulators worldwide with accurate information and create a "stable framework."

 

In his keynote, Murphy shared his experiences and stated that the dual themes of the forum have dual significance in "promoting public health" and "focusing on social welfare."

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
James Murphy, Director of Research and Science at British American Tobacco (BAT)

 

Deepening the Discussion on Nicotine and E-Cigarettes

 

The first panel discussion invited several industry experts to delve deeper into misunderstandings and myths about nicotine and e-cigarettes. The discussion was moderated by Jasjit Ahluwalia, Professor of Behavioral and Social Sciences and Professor of Medicine at Brown University School of Public Health and Alpert Medical School. The panelists included Delon Human, family doctor and president of the "Health Diplomats" group, Dave Dobbins, former COO of the American Legacy Foundation/Truth Initiative, and Sudhanshu Patwardhan, nicotine expert and health technology entrepreneur.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The first panel discussion deepened the discussion on misunderstandings and myths about nicotine and e-cigarettes

 

Ahluwalia noted that over the past decade, as the e-cigarette market has grown, the idea that "e-cigarettes are more harmful than traditional combustible cigarettes" has gained traction among smokers, leading many who had switched to e-cigarettes to return to smoking. He described this as "incredible"; the panelists agreed that the industry should invest more resources in related research to combat the "horror narrative" with science.

 

Dobbins, from a market perspective, discussed the proper direction for regulating nicotine products from the standpoint of human rights and legal principles. He argued that every adult's actions and choices are their own responsibility, and thus "adults need to be treated as adults, not managed with flavor bans or outright prohibitions on nicotine intake methods."

 

Nicotine from an Agricultural Perspective: Ensuring Farmers' Interests

 

The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers, an area less frequently highlighted by the industry. The session included George Cassels-Smith, CEO of a tobacco technology company, Ramsey S. Lewis, Professor of Plant Breeding at North Carolina State University, Carlos Pulcinelli, Global Project Manager at Alliance One International, and Lea Scott, Senior Vice President of Universal Leaf Tobacco Co.

 

GTNF InFocus 2024: Misperception of Nicotine as Well as an Agricultural Approach for It
The second panel discussion focused on the upstream tobacco farming and the welfare of related farmers

 

During the discussion, the panelists analyzed the development of upstream tobacco farming from the perspectives of tobacco farmers, buyers, and regulators across the supply chain. They emphasized the critical importance of tobacco leaf quality for all stakeholders. Professor Lewis highlighted the success of developing high-quality, high-yield, disease-resistant tobacco varieties through genetic modification over the past decade. He suggested that future research and development to increase the added value of raw tobacco leaves would be a significant focus for the industry.

 

The panelists unanimously agreed that not everyone realizes that nicotine, like large-scale agriculture in livestock and crops, involves a "farm-to-table" process. Ensuring the interests of farmers who grow tobacco is essential to meet the increasing ESG (Environmental, Social, and Governance) requirements from regulators and society for nicotine companies.

 

 

About GTNF InFocus


 

InFocus is the largest online tobacco and nicotine conference. Bringing together thought leaders, industry voices, and leaf and public health experts。
 

2FIRSTS focused on the core topics and significant viewpoints of the forum, conducting in-depth interviews with government officials, business executives, and industry experts from various countries. We published over 20 high-quality reports in both text and video formats.

This series of reports not only promoted GTNF's global reach but also provided valuable information and profound insights for the high-quality development of the e-cigarette industry.

Here is an overview of key content covered by 2FIRSTS at GTNF 2023:

1. FDA CTP Director Brian King: Submitting PMTA is No Equivalent to Legal Sale
 https://www.2firsts.com/news/fda-director-brian-king-on-e-cigarette-compliance-and-tracking-systems

2. GTNF 2023: Sustainable Development and New Vape Products
https://www.2firsts.com/news/the-future-of-e-cigarettes-sustainable-development-and-new-products

3. GTNF Discusses Addressing Youth Misuse of Harm Reduction Products: A Collaborative Effort Needed
 https://www.2firsts.com/news/gtnf-discusses-addressing-youth-misuse-of-harm-reduction-products-a-collaborative-effort-needed

4. Interview with GTNF Founder: Transform Industry Through Unique Dialogues
https://www.2firsts.com/news/interview-with-gtnf-founder-transform-industry-through-unique-dialogues

Moving forward, 2FIRSTS will continue to closely track the latest developments and trends in the e-cigarette industry, committed to providing readers with cutting-edge information and in-depth analysis. This ensures that readers receive accurate and comprehensive first-hand industry updates promptly.

 

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20